Successful treatment of Hodgkin lymphoma in second trimester of pregnancy: feasibility of ABVD regimen

被引：0

作者：

Noriyoshi Iriyama

Akira Horikoshi

Toshitake Tanaka

Yukio Hirabayashi

Hitomi Kodaira

Yoshihiro Hatta

Jin Takeuchi

机构：

[1] Nerima-Hikarigaoka Hospital,Department of Internal Medicine, Nihon University School of Medicine

[2] Itabashi Hospital,Department of Hematology and Rheumatology, Nihon University School of Medicine

来源：

International Journal of Hematology | 2011年 / 94卷

关键词：

Hodgkin lymphoma; Pregnancy; Chemotherapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

A 34-year-old woman at 18 weeks of gestation during her third pregnancy was diagnosed with Hodgkin lymphoma stage IVA. She was treated with standard ABVD and showed good response. After three-and-a-half courses of ABVD, she spontaneously delivered a healthy baby girl at 41 weeks of gestation. She continued chemotherapy after delivery. A total of six courses of ABVD were given. Complete remission was obtained and has continued for 6 months post chemotherapy. Neither mother nor child developed any infections during the observation period. The child has also shown no physiological or developmental abnormalities. Here, we describe the feasibility and safety of the ABVD regimen for the treatment of Hodgkin lymphoma, and discuss the optimal treatment strategy.

引用

页码：104 / 107

页数：3

共 50 条

[21] Successful management of severe idiopathic thrombocytopenia in the second trimester of pregnancy
Antsaklis, A
Papageorgiu, I
Sindos, M
Katsimanis, E
Karaiskakis, P
Michalas, S
FETAL DIAGNOSIS AND THERAPY, 1998, 13 (04) : 233 - 235
[22] The Hybrid Regimen of ABVD/BEACOPP May Overcome the High-Risk Features of the Advanced Stage Hodgkin Lymphoma
Alaskar, Ahmed
Al Ameer, Ahmad
Ahmed, Gasmelseed
Alhejazi, Ayman
Abuelgasim, Khadega
Gmati, Giamal
Rather, Mushtaq
Al Zahrani, Mohsen
BLOOD, 2014, 124 (21)
[23] The choice of first-line therapy in advanced Hodgkin lymphoma: Retrospective comparison of ABVD and escalated BEACOPP regimen
Jurczak, W., Sr.
Krochmalczyk, D.
Giza, A.
Wegrzyn, J.
Sobocinski, M.
Gawelko, J.
Malkowski, B.
Czyz, J.
Pawlega, J.
Skotnicki, A. B.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[24] The role of second autografts in the treatment of Hodgkin lymphoma
Ritchie, David S.
LEUKEMIA & LYMPHOMA, 2007, 48 (05) : 847 - 848
[25] Successful pregnancy and fetal outcome following previous treatment with pembrolizumab for relapsed Hodgkin's lymphoma
Le-Nguyen, Alexandre
Rys, Ryan N.
Petrogiannis-Haliotis, Tina
Johnson, Nathalie A.
CANCER REPORTS, 2022, 5 (01)
[26] Hodgkin's Lymphoma in Paediatric Population: Analysis of Short Term Outcomes with ABVD and Non ABVD Based Treatment Protocols
Jadhav, N.
Dubashi, B.
Kayal, S.
Madasamy, P.
Pattnaik, J.
Singh, J.
Paramanandhan, M.
Jafa, E.
PEDIATRIC BLOOD & CANCER, 2017, 64 : S208 - S208
[27] Randomised Comparison of the Stanford V (SV) Regimen and ABVD in the Treatment of Advanced Hodgkin Lymphoma (HL): Results from a UK NCRI Lymphoma Group Study, ISRCTN 64141244
Johnson, Peter W. M.
Horwich, Alan
Jack, Andrew
Mead, Graham
Hancock, Barry
Smith, Paul
Qian, Wendi
Patrick, Philippa
Pettitt, Andrew
Cunningham, David
Hoskin, Peter
BLOOD, 2008, 112 (11) : 144 - 144
[28] Report on the Treatment of Hodgkin Lymphoma with ABVD Chemotherapy at Two Rural District Hospitals in Rwanda
Shyirambere, Cyprien
Deboer, Rebecca
Butera, Yvan
Driscoll, Caitlin
Bigirimana, Jean Bosco
Uwizeye, Francois Regis
Fadelu, Temidayo
Park, Paul H.
Paciorek, Alan
Lehmann, Leslie E.
Shulman, Lawrence N.
BLOOD, 2019, 134
[29] Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery
Schwenkglenks, M.
Pettengell, R.
Culakova, E.
Lyman, G. H.
EJC SUPPLEMENTS, 2009, 7 (02): : 567 - 567
[30] ABVD IN TREATMENT OF GENERATIVE AGE FEMALES WITH ADVANCED HODGKIN LYMPHOMA - A RISK FACTOR ANALYSIS
Andjelic, B.
Todorovic, M.
Antic, D.
Bila, J.
Jakovic, L.
Sretenovic, A.
Djurasinovic, V.
Vukovic, V.
Jelicic, J.
Smiljanic, M.
Mihaljevic, B.
HAEMATOLOGICA, 2014, 99 : 400 - 401

← 1 2 3 4 5 →